IOVANCE BIOTHERAPEUTICS, INC.

Listed Company

IOVACIK 0001425205NasdaqAcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$263.50M

Net Income

$-391.00M

Total Assets

$913.17M

Equity

$698.58M

Shares Out

446.50M

Op. Cash Flow

$-302.40M

IOVA$4.99+111.44% · past yearDBEQ Basic

Daily closing prices

Business

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company developing tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers. The company offers Amtagvi® (lifileucel), the first FDA-approved individualized TIL cell therapy for previously treated advanced melanoma, and Proleukin® (aldesleukin), an interleukin-2 product used in the Amtagvi® treatment regimen and other oncology applications. Iovance operates through a centralized manufacturing facility in Philadelphia and is investigating next-generation TIL therapies in clinical trials for melanoma, non-small cell lung cancer, and other solid tumors across global markets.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	264	164	1	—	—
Cost of sales	173	93	1	—	—
Research and development	300	276	333	295	259
Selling, general, and administrative	152	152	106	104	84
Depreciation and amortization	36	38	21	—	—
Restructuring charges	5	—	—	—	—
Total costs and expenses	667	559	462	399	343
Loss from operations	−403	−395	−461	−399	−343
Interest and other income, net	10	20	13	3	451,000
Net Loss before income taxes	−393	−375	−448	−396	−342
Income tax (expense) benefit	2	3	4	0	0
Net Loss	−391	−372	−444	−396	−342
Net Loss Per Share of Common Stock, Basic (in dollars per share)	−1.09	−1.28	−1.89	−2.49	−2.23
Net Loss Per Share of Common Stock, Diluted (in dollars per share)	−1.09	−1.28	−1.89	−2.49	−2.23
Weighted Average Shares of Common Stock Outstanding, Basic (in shares)	357,345	289,877	235,131	159,259	153,406
Weighted Average Shares of Common Stock Outstanding, Diluted (in shares)	357,345	289,877	235,131	159,259	153,406
Non-cash stock-based compensation included in cost of sales	7	9	—	—	—
Non-cash stock-based compensation included in research and development	27	49	35	—	—
Non-cash stock-based compensation included in selling, general and administrative	27	52	28	—	—
Share-based Compensation	62	110	63	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	163	116	115	232	78
Trade accounts receivable	82	69	151,000	—	—
Short-term investments	134	208	165	240	426
Inventory	52	52	10	—	—
Prepaid expenses and other assets	12	12	17	7	4
Total Current Assets	443	457	308	479	508
Property and equipment, net	131	109	114	105	101
Intangible assets, net	279	282	229	—	—
Operating lease right-of-use assets	46	55	63	73	69
Restricted cash	6	6	66	—	—
Long-term assets	8	369,000	270,000	189,000	2
Total Assets	913	910	780	664	777
Accounts payable	22	28	33	27	27
Accrued expenses and other liabilities	111	82	69	—	—
Note payable - current	1	—	—	—	—
Operating lease liabilities	4	13	8	13	5
Total Current Liabilities	138	122	110	91	89
Operating lease liabilities - non-current	44	44	67	72	65
Deferred tax liabilities	32	32	17	—	—
Long-term note payable	—	1	1	1	1
Total Non-Current Liabilities	76	78	85	73	66
Total Liabilities	215	200	196	164	156
Commitments and contingencies	—	—	—	—	—
Common stock, $0.000041666 par value; 500,000,000 shares authorized, 411,938,061 and 305,252,194 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	17,000	13,000	11,000	8,000	7,000
Accumulated other comprehensive income (loss)	16	−1	3	−902,000	−601,000
Additional paid-in capital	3,458	3,096	2,594	2,069	1,795
Accumulated deficit	−2,776	−2,385	−2,012	−1,568	−1,172
Total Stockholders' Equity	699	710	585	500	622
Total Liabilities and Stockholders' Equity	913	910	780	664	777

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	62	110	63	84	70
Unrealized foreign exchange loss	−238,000	−175,000	70,000	—	—
Amortization of intangible assets	23	26	10	0	—
Amortization of right of use asset	11	10	12	12	11
Depreciation and amortization of property and equipment	13	11	12	9	3
Deferred tax (benefit) expense	−2	−3	−3	—	—
Excess and obsolescence reserve	13	—	—	—	—
Accretion of discounts and premiums on investments	−7	−10	−4	474,000	6
Loss on asset disposals	44,000	7	—	—	—
Gain on derecognition of lease assets and liabilities	—	−6	—	—	—
Prepaid expenses, other assets and long-term assets	−8	−2	−10	−2	3
Trade accounts receivable	−13	−69	−149,000	—	—
Inventory	−14	−44	−10	—	—
Operating lease liabilities	−11	−12	−11	−2	−6
Accounts payable	−7	−8	5	6	7
Accrued expenses and other liabilities	29	9	20	−5	21
Net cash used in operating activities	−302	−353	−362	−293	−228
Maturities of investments	400	428	286	523	763
Purchase of investments	−319	−461	−206	−246	−725
Cash paid for acquisition, including contingent consideration, net of cash acquired	—	−53	−213	—	—
Purchase of property and equipment	−34	−11	−22	−20	−38
Net cash provided by (used in) investing activities	47	−96	−155	256	132,000
Tax payments related to shares withheld for vested restricted stock units	−7	−13	−3	−3	—
Proceeds from the issuance of common stock under employee stock purchase plan	2	3	2	2	—
Proceeds from the issuance of common stock upon exercise of options	15,000	3	63,000	2	34
Proceeds from the issuance of common stock, net	306	397	463	190	203
Net cash provided by financing activities	301	391	463	190	239
Effect of foreign exchange rate changes	1	−541,000	−3	—	—
Net increase (decrease) in cash, cash equivalents and restricted cash	47	−59	−57	154	11
Fair value of net assets acquired	—	—	223	—	—
Net unrealized loss on investments	54,000	78,000	940,000	−301,000	−620,000
Acquisition of property and equipment included in accounts payable and accrued expenses	9	7	4	6	−12
Intangible asset and deferred tax liability arising from contingent consideration	—	17	—	—	—
Conversion of convertible preferred stock to common stock	1,000	—	—	—	1,000
Lease liabilities arising from obtaining right-of-use asset from new leases	—	2	177,000	553,000	17
Increase / (decrease) in lease liabilities due to obtaining/(reduction in) right-of-use assets from lease modifications	2	−8	1	15	8

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is IOVANCE BIOTHERAPEUTICS, INC.'s CIK number?

IOVANCE BIOTHERAPEUTICS, INC.'s SEC CIK number is 0001425205 (1425205). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find IOVANCE BIOTHERAPEUTICS, INC.'s SEC filings?

All of IOVANCE BIOTHERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did IOVANCE BIOTHERAPEUTICS, INC. last report earnings?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-056782). This is IOVANCE BIOTHERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is IOVANCE BIOTHERAPEUTICS, INC.'s most recent earnings 8-K?

IOVANCE BIOTHERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-056782. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View IOVANCE BIOTHERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →